[HTML][HTML] Multiple myeloma current treatment algorithms
The treatment of multiple myeloma (MM) continues to evolve rapidly with arrival of multiple
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
new drugs, and emerging data from randomized trials to guide therapy. Along the disease …
Proteasome inhibitors in cancer therapy
EE Manasanch, RZ Orlowski - Nature reviews Clinical oncology, 2017 - nature.com
The ubiquitin proteasome pathway was discovered in the 1980s to be a central component
of the cellular protein-degradation machinery with essential functions in homeostasis, which …
of the cellular protein-degradation machinery with essential functions in homeostasis, which …
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management
SV Rajkumar - American journal of hematology, 2022 - Wiley Online Library
Abstract Disease Overview Multiple myeloma accounts for approximately 10% of
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
hematologic malignancies. Diagnosis The diagnosis requires≥ 10% clonal bone marrow …
Daratumumab plus lenalidomide and dexamethasone for untreated myeloma
Background Lenalidomide plus dexamethasone is a standard treatment for patients with
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell …
[HTML][HTML] Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma
M Attal, V Lauwers-Cances, C Hulin… - … England Journal of …, 2017 - Mass Medical Soc
Background High-dose chemotherapy plus autologous stem-cell transplantation has been
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …
the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of …
[HTML][HTML] Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma
Background The combination of bortezomib, melphalan, and prednisone is a standard
treatment for patients with newly diagnosed multiple myeloma who are ineligible for …
treatment for patients with newly diagnosed multiple myeloma who are ineligible for …
Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma
Background Ixazomib is an oral proteasome inhibitor that is currently being studied for the
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …
treatment of multiple myeloma. Methods In this double-blind, placebo-controlled, phase 3 …
[HTML][HTML] Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
Background Lenalidomide plus dexamethasone is a reference treatment for relapsed
multiple myeloma. The combination of the proteasome inhibitor carfilzomib with …
multiple myeloma. The combination of the proteasome inhibitor carfilzomib with …
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for …
Background Lenalidomide plus dexamethasone is a reference treatment for patients with
newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with …
newly diagnosed myeloma. The combination of the proteasome inhibitor bortezomib with …
[HTML][HTML] Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Since the publication of the article entitled “Multiple Myeloma: EHA-ESMO Clinical Practice
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …
Guidelines for Diagnosis, Treatment and Follow-up”(HemaSphere. 2021; 5: e528) …